Connect Sign In
Drawing on ARUP experts' extensive knowledge about the diagnosis and treatment of cerebral creatine deficiency syndromes, a new initiative seeks answers for those with creatine transporter deficiency.
Rong Mao, MD, FACMG, looks forward to bridging the gap between laboratory and clinical practice after her recent election to the ACMGF board of directors, and will present at the ACMG meeting.
Allison Carey, MD, PhD, ARUP medical director of Hematopathology, was one of six U faculty members recognized for research excellence and invited to share their stories at the Vitae 2022 symposium.
For 20-plus years, Mark Withers had inexplicable episodes of a severe anaphylaxis-like phenomenon. ARUP’s unique expertise and highly sensitive tests help patients like him find the right diagnosis.
Laboratory-developed tests made up only about 4% of an academic health system’s total test orders in 2021, yet they played an important role in patient care, a new study shows.
The near total automation installed in ARUP’s Automated Core Lab increases capacity for testing, provides better turnaround times, reduces risk of human error, and improves staff satisfaction.
ARUP’S new test is the first of its kind to use two distinct biomarkers to identify in utero exposure to kratom, an herbal supplement that may cause neonatal abstinence syndrome.
The Fall 2022 edition of Magnify: The Art and Science of Diagnostic Medicine, shares how ARUP has applied what it learned from COVID-19 to improve operations, services, and, ultimately, patient care.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
Based on data from 21,916 participants in 33 studies, the Association for the Advancement of Blood and Biotherapies (AABB) has issued guidelines for use of convalescent plasma in COVID-19 treatment.
The National Institute of Allergy and Infectious Diseases has awarded Medical Director Allison Carey, MD, PhD, $1.5 million over five years to fund her groundbreaking research.
NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership.
